FG 001
Alternative Names: FG-001; FG001 sodium; ICG-Glu-Glu-AE105Latest Information Update: 08 Jul 2026
At a glance
- Originator FluoGuide
- Class Diagnostic agents; Diagnostic conjugates; Imaging agents; Small molecules
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Yes - Glioma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Glioblastoma; Glioma; Head and neck cancer; Meningioma; Non-small cell lung cancer; Squamous cell cancer
- No development reported Pancreatic cancer
Most Recent Events
- 01 Jul 2026 FluoGuide plans a first patient enrollemtn in a phase II registration trial for Glioma in the US in July 2026
- 29 Jun 2026 Updated efficacy and safety data from a phase II FG001-CT-005 trial released by FluoGuide
- 08 Jun 2026 FluoGuide plans a phase II trial in Squamous cell cancer in Denmark (IV) in July 2026 (CTIS2025-522845-23-00)